Lantheus Holdings, Inc. (NASDAQ:LNTH) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have been given an average recommendation of “Moderate Buy” by the eight research firms that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $125.71.

A number of analysts have recently weighed in on the company. JMP Securities cut their price objective on Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a research report on Thursday, November 7th. Truist Financial restated a “buy” rating and issued a $120.00 price objective (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Finally, Redburn Atlantic initiated coverage on Lantheus in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price target on the stock.

Institutional Trading of Lantheus

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Tidal Investments LLC grew its stake in Lantheus by 25.2% during the 3rd quarter. Tidal Investments LLC now owns 17,621 shares of the medical equipment provider’s stock worth $1,934,000 after buying an additional 3,547 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new position in shares of Lantheus during the third quarter worth approximately $25,000. World Investment Advisors LLC acquired a new position in shares of Lantheus in the 3rd quarter valued at $60,000. Hohimer Wealth Management LLC purchased a new stake in Lantheus in the 3rd quarter valued at $250,000. Finally, Coldstream Capital Management Inc. acquired a new stake in Lantheus during the 3rd quarter worth $230,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Trading Down 1.1 %

Shares of LNTH opened at $89.27 on Monday. Lantheus has a 12-month low of $50.20 and a 12-month high of $126.89. The firm has a 50-day moving average price of $101.34 and a 200 day moving average price of $97.37. The firm has a market capitalization of $6.21 billion, a P/E ratio of 14.85 and a beta of 0.51.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.